These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20184575)

  • 21. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk reduction therapy for syndrome X: comparison of several treatments.
    Oron-Herman M; Sela BA; Rosenthal T
    Am J Hypertens; 2005 Mar; 18(3):372-8. PubMed ID: 15797656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of Liuweidihuang pills on plasma adiponectin level in OLETF rats].
    Qian Y; Xue YM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):34-6. PubMed ID: 18227021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
    Ogawa M; Hirawa N; Tsuchida T; Eguchi N; Kawabata Y; Numabe A; Negoro H; Hakamada-Taguchi R; Seiki K; Umemura S; Urade Y; Uehara Y
    Nephrol Dial Transplant; 2006 Apr; 21(4):924-34. PubMed ID: 16384826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of cholecystokinin in baseline and post-prandial whole body insulin sensitivity in rats.
    Peitl B; Döbrönte R; Drimba L; Sári R; Varga A; Németh J; Pázmány T; Szilvássy Z
    Eur J Pharmacol; 2010 Oct; 644(1-3):251-6. PubMed ID: 20624386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental rat models to study the metabolic syndrome.
    Aleixandre de Artiñano A; Miguel Castro M
    Br J Nutr; 2009 Nov; 102(9):1246-53. PubMed ID: 19631025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
    Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
    Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature.
    Türkoglu C; Duman BS; Günay D; Cagatay P; Ozcan R; Büyükdevrim AS
    Obes Surg; 2003 Oct; 13(5):699-705. PubMed ID: 14627463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes medications and cancer: a way out of uncertainty.
    Gallo M; Esposito K; Giugliano D
    Diabetes Res Clin Pract; 2012 Aug; 97(2):175-7. PubMed ID: 22560795
    [No Abstract]   [Full Text] [Related]  

  • 32. [Relationship between metabolic syndrome and urinary stone disease].
    Yamaguchi S
    Clin Calcium; 2011 Oct; 21(10):1489-95. PubMed ID: 21960234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.
    Inokuchi J
    Handb Exp Pharmacol; 2011; (203):165-78. PubMed ID: 21484572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of thiazolidinediones on cardiovascular risk factors.
    Gouda BP; Asnani S; Fonseca VA
    Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Characteristics of the therapy of patients with type II diabetes mellitus and metabolic syndrome].
    Bodnar PM; Kononenko LO
    Lik Sprava; 2000; (7-8):92-4. PubMed ID: 16786661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II receptor blockers and insulin resistance.
    Ciccarelli L
    Hypertens Res; 2010 Aug; 33(8):779. PubMed ID: 20535122
    [No Abstract]   [Full Text] [Related]  

  • 37. [Basic concept for the treatment of metabolic syndrome].
    Katayama S
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():566-70. PubMed ID: 21766661
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of angiotensin II receptor blockers on insulin resistance.
    Ragonesi PD
    Hypertens Res; 2010 Aug; 33(8):778. PubMed ID: 20555329
    [No Abstract]   [Full Text] [Related]  

  • 39. The metabolic syndrome: looking beyond the debates.
    Prabhakaran D; Reddy KS
    Clin Pharmacol Ther; 2011 Jul; 90(1):19-21. PubMed ID: 21691269
    [No Abstract]   [Full Text] [Related]  

  • 40. [Diabetes mellitus and metabolic syndrome in epidemiological studies].
    Sone H
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():93-100. PubMed ID: 21766579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.